The Correlation Between Pre-Treatment Inflammatory Markers and the Treatment of Breast Cancer
Versandkostenfrei!
Versandfertig in 1-2 Wochen
35,99 €
inkl. MwSt.
PAYBACK Punkte
18 °P sammeln!
There is increasing evidence demonstrating that systemic inflammation is critically involved in promoting tumor progression and metastasis. Inflammatory markers, including neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) or lymphocyte/monocyte ratio (LMR) may partially reflect the immune function in the body. Numerous researches have shown that increased NLR, PLR and LMR are associated with poor prognosis in BC.The predictive significance of pre-treatment NLR / PLR / LMR for and neoadjuvant therapy (NAC) efficacyis not fully understood, and the results were controversial. Her...
There is increasing evidence demonstrating that systemic inflammation is critically involved in promoting tumor progression and metastasis. Inflammatory markers, including neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) or lymphocyte/monocyte ratio (LMR) may partially reflect the immune function in the body. Numerous researches have shown that increased NLR, PLR and LMR are associated with poor prognosis in BC.The predictive significance of pre-treatment NLR / PLR / LMR for and neoadjuvant therapy (NAC) efficacyis not fully understood, and the results were controversial. Herein, this study was designed to assess the correlation of pre-treatment NLR, PLR and LMR with menopausal status and Ki67 LI, and to determine whether they were predictive factors for NAC responses. This is the first case report describing a patient with non-small cell lung cancer (NSCLC) harboring two rare human epidermal growth factor receptor 2 (HER2) exon 21 insertion mutations, who responded to furmonertinib treatment.
Andere Kunden interessierten sich für
